Bloomage Biotechnology Corporation Limited(688363) 3 on March 10, the annual performance report of 2021 was released. During the reporting period, the operating revenue reached 4.948 billion yuan, a year-on-year increase of 87.93%; The net profit attributable to shareholders of listed companies was 782 million yuan, an increase of 21.13% year-on-year; The net operating cash flow was 1.276 billion yuan, a year-on-year increase of 80.97%. On March 14, Bloomage Biotechnology Corporation Limited(688363) held a media communication meeting to respond to the problems that the growth rate of net profit was lower than that of revenue and the growth rate of sales expenses was fast.
In 2021, Bloomage Biotechnology Corporation Limited(688363) based on its main business segment, continued to strengthen market development, continuously launched products in market demand, and realized that the sales revenue of functional skin care products increased by 1.973 billion yuan over the previous year, an increase of 146.57%. The four major brands (runbaiyan, kuadi, mibeier and BM Jihuo) passed the initial growth period of the brand and entered the stage of large-scale, And the annual revenue of single brand (runbaiyan) exceeded 1 billion for the first time. The sales revenue of raw material products and medical end products also continued to grow, with a year-on-year increase of 28.62% and 21.54% respectively. The brand of “aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua, aqua.
Compared with the revenue, the growth rate of Bloomage Biotechnology Corporation Limited(688363) net profit is somewhat weak. In this regard, Zhao Yan, chairman and general manager of Bloomage Biotechnology Corporation Limited(688363) responded that Huaxi has always adhered to basic research and application, with relatively large strategic and R & D investment. For example, in 2021, the field of Frontier Biotechnologies Inc(688221) technology “synthetic biology” has not been converted into productivity and is still in the reserve stage. In addition, there is also a lot of investment in capacity construction, including Tianjin factory, Bloomage Biotechnology Corporation Limited(688363) (Haikou) science and Technology Industrial Park, Dongying aseptic workshop, talent reserve, etc.
Bloomage Biotechnology Corporation Limited(688363) ‘s expense rate has also attracted much attention. In 2021, Bloomage Biotechnology Corporation Limited(688363) sales expenses reached 2.436 billion yuan, with a year-on-year increase of 121.72%. Zhao Yan explained that the initial investment in brand construction is large, and the cost rate will gradually decline with the gradual maturity of the brand Bloomage Biotechnology Corporation Limited(688363) deputy general manager Li Yizheng also said that behind the rapid growth of expense rate is the rapid growth of business. For example, the functional skin care business achieved a revenue of 3.320 billion yuan in 2021, a year-on-year increase of 146.57%.
In 2022, Bloomage Biotechnology Corporation Limited(688363) will focus on the “five dimensions”, focusing on the construction of synthetic biology R & D platform at the R & D end; Strengthen the construction of talent echelon and stimulate talent self drive; Build a national brand with temperature and national trust; Continue to build a new ecology of science and technology and empower the upstream and downstream; Actively undertake social responsibility and help rural revitalization.
